395 related articles for article (PubMed ID: 17161457)
1. Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes.
Olney HJ; Le Beau MM
Leuk Res; 2007 Apr; 31(4):427-34. PubMed ID: 17161457
[TBL] [Abstract][Full Text] [Related]
2. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.
Haferlach C; Bacher U; Tiu R; Maciejewski JP; List A
Cancer Genet Cytogenet; 2008 Dec; 187(2):101-11. PubMed ID: 19027491
[TBL] [Abstract][Full Text] [Related]
3. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
Nimer SD
J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
[TBL] [Abstract][Full Text] [Related]
4. Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup.
Giagounidis AA; Germing U; Strupp C; Hildebrandt B; Heinsch M; Aul C
Ann Hematol; 2005 Sep; 84(9):569-71. PubMed ID: 15891887
[TBL] [Abstract][Full Text] [Related]
5. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
[TBL] [Abstract][Full Text] [Related]
6. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.
Heise C; Carter T; Schafer P; Chopra R
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1663-72. PubMed ID: 20942636
[TBL] [Abstract][Full Text] [Related]
7. Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion.
Oliva EN; Cuzzola M; Nobile F; Ronco F; D'Errigo MG; Laganà C; Morabito F; Galimberti S; Cortelezzi A; Aloe Spiriti MA; Specchia G; Poloni A; Breccia M; Ghio R; Finelli C; Iacopino P; Alimena G; Latagliata R
Eur J Haematol; 2010 Sep; 85(3):231-5. PubMed ID: 20491881
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow morphology predicts additional chromosomal abnormalities in patients with myelodysplastic syndrome with del(5q).
Geyer JT; Verma S; Mathew S; Wang YL; Racchumi J; Espinal-Witter R; Subramaniyam S; Knowles DM; Orazi A
Hum Pathol; 2013 Mar; 44(3):346-56. PubMed ID: 22995330
[TBL] [Abstract][Full Text] [Related]
9. Unusual clonal evolution involving 5q in a case of myelodysplastic syndrome with deletion 5q 31 treated with lenalidomide.
Eclache V; Da Rocha A; Le Roux G; Fenaux P
Haematologica; 2008 Feb; 93(2):315-6. PubMed ID: 18245660
[TBL] [Abstract][Full Text] [Related]
10. Cytogenetic aspects of adult primary myelodysplastic syndromes: clinical implications.
Panani AD; Roussos C
Cancer Lett; 2006 Apr; 235(2):177-90. PubMed ID: 15935553
[TBL] [Abstract][Full Text] [Related]
11. Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide.
Breccia M; Cannella L; Latagliata R; Nanni M; Santopietro M; Loglisci G; Ferretti A; Barzotti R; Oliva EN; Alimena G
Leuk Res; 2011 Jun; 35(6):e69-70. PubMed ID: 21232796
[No Abstract] [Full Text] [Related]
12. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies.
Giagounidis AA; Germing U; Aul C
Clin Cancer Res; 2006 Jan; 12(1):5-10. PubMed ID: 16397017
[TBL] [Abstract][Full Text] [Related]
13. The role of lenalidomide in the management of myelodysplasia with del 5q.
Kelaidi C; Eclache V; Fenaux P
Br J Haematol; 2008 Feb; 140(3):267-78. PubMed ID: 18217896
[TBL] [Abstract][Full Text] [Related]
14. [Chromosomal aberrations in myelodysplastic syndrome].
Ol'shanskaia IuV; Domracheva EV; Udovichenko AI; Vodinskaia LA; Zakharova AV; Parovichnikova EN; Tsvetaeva NV; Mikhaĭlova EA; Glasko EN; Kolosova LIu; Kokhno AN; Tikhonova LIu; Shitareva TV; Smirnova EA; Alimova GA; Shirin AD; Vinogradova OIu; Khoroshko ND; Savchenko VG
Ter Arkh; 2005; 77(7):27-33. PubMed ID: 16116905
[TBL] [Abstract][Full Text] [Related]
15. Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.
Matsuda A; Taniwaki M; Jinnai I; Harada H; Watanabe M; Suzuki K; Yanagita S; Suzuki T; Yoshida Y; Kimura A; Tsudo M; Tohyama K; Takatoku M; Ozawa K
Leuk Res; 2012 May; 36(5):575-80. PubMed ID: 22172461
[TBL] [Abstract][Full Text] [Related]
16. Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide.
Sugimoto Y; Sekeres MA; Makishima H; Traina F; Visconte V; Jankowska A; Jerez A; Szpurka H; O'Keefe CL; Guinta K; Afable M; Tiu R; McGraw KL; List AF; Maciejewski J
J Hematol Oncol; 2012 Mar; 5():4. PubMed ID: 22390313
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses.
Giagounidis AA; Haase S; Heinsch M; Göhring G; Schlegelberger B; Aul C
Ann Hematol; 2007 Feb; 86(2):133-7. PubMed ID: 17111142
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis.
Matsuoka A; Tochigi A; Kishimoto M; Nakahara T; Kondo T; Tsujioka T; Tasaka T; Tohyama Y; Tohyama K
Leukemia; 2010 Apr; 24(4):748-55. PubMed ID: 20130600
[TBL] [Abstract][Full Text] [Related]
19. [Detection of cytogenetic abnormalities involving chromosomes 5,7 and 8 in myelodysplastic syndromes with fluorescence in situ hybridization and its clinical significance].
Cai Y; Qin YW; Wang C; Yang J; Yan SK
Zhonghua Xue Ye Xue Za Zhi; 2007 Jan; 28(1):6-10. PubMed ID: 17649717
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of lenalidomide treatment and complete cytogenetic remission in a case of myelodysplastic syndrome with del(5q) and del(9q).
Xiong B; Liu X; Zou P; Fan L; Chen W; Li W; Liu L
Leuk Res; 2010 Jul; 34(7):e169-72. PubMed ID: 20122730
[No Abstract] [Full Text] [Related]
[Next] [New Search]